Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
Authors
Keywords
Antibodies, Antigens, Protein engineering, Engineering and technology, Monkeys, Antibody engineering, Blood plasma, Elimination half-life calculation
Journal
PLoS One
Volume 13, Issue 12, Pages e0209509
Publisher
Public Library of Science (PLoS)
Online
2018-12-29
DOI
10.1371/journal.pone.0209509
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eculizumab: A Review in Generalized Myasthenia Gravis
- (2018) Sohita Dhillon DRUGS
- “Catch-and-Release” Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer
- (2018) Frank A. Engler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
- (2018) Douglas Sheridan et al. PLoS One
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
- (2018) Johnny Mahlangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
- (2017) Srinath Kasturirangan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
- (2017) Danlin Yang et al. mAbs
- Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody
- (2017) Atsuhiko Maeda et al. mAbs
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) Johannes Oldenburg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Next Generation Antibody Therapeutics Using Bispecific Antibody Technology
- (2017) Tomoyuki Igawa YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
- Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
- (2017) Taku Fukuzawa et al. Scientific Reports
- Engineering antibody therapeutics
- (2016) Mark L Chiu et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody–antigen binding model
- (2016) Kenta Haraya et al. Drug Metabolism and Pharmacokinetics
- Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
- (2016) Tomoyuki Igawa et al. IMMUNOLOGICAL REVIEWS
- Immunogenicity of Therapeutic Protein Aggregates
- (2016) Ehab M. Moussa et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life
- (2016) Abhishek Saxena et al. Frontiers in Immunology
- Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering
- (2015) Yuki Iwayanagi et al. JOURNAL OF IMMUNOLOGY
- De novoisolation of antibodies with pH-dependent binding properties
- (2015) Pauline Bonvin et al. mAbs
- Complement and Its Receptors: New Insights into Human Disease
- (2014) V. Michael Holers Annual Review of Immunology
- pH-dependent antigen-binding antibodies as a novel therapeutic modality
- (2014) T. Igawa et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display
- (2014) Christian Schröter et al. mAbs
- Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
- (2014) Bing Li et al. mAbs
- Genetic Variants in C5 and Poor Response to Eculizumab
- (2014) Jun-ichi Nishimura et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics
- (2013) Siva Charan Devanaboyina et al. mAbs
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
- (2013) C.M. Legendre et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
- (2013) Zenjiro Sampei et al. PLoS One
- Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo
- (2013) Tomoyuki Igawa et al. PLoS One
- Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates
- (2012) Karen J. Vincent et al. Biotechnology Journal
- C-terminal modification of monoclonal antibody drugs: Amidated species as a general product-related substance
- (2012) Masahiro Tsubaki et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9
- (2012) Javier Chaparro-Riggers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Engineering the variable region of therapeutic IgG antibodies
- (2011) Tomoyuki Igawa et al. mAbs
- A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches
- (2011) Megan L. Murtaugh et al. PROTEIN SCIENCE
- Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys
- (2010) Jim J. Xiao et al. AAPS Journal
- Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
- (2010) Takuo Suzuki et al. JOURNAL OF IMMUNOLOGY
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
- (2010) Tomoyuki Igawa et al. NATURE BIOTECHNOLOGY
- Reduced elimination of IgG antibodies by engineering the variable region
- (2010) T. Igawa et al. PROTEIN ENGINEERING DESIGN & SELECTION
- T cell epitope: Friend or Foe? Immunogenicity of biologics in context☆
- (2009) Constanze A. Weber et al. ADVANCED DRUG DELIVERY REVIEWS
- Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
- (2009) Philip J. Lowe et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Characterization of antibody aggregation: Role of buried, unpaired cysteines in particle formation
- (2009) Stephen R. Brych et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Therapeutic potential of complement modulation
- (2009) Eric Wagner et al. NATURE REVIEWS DRUG DISCOVERY
- Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"
- (2008) A. S. De Groot et al. BLOOD
- Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
- (2008) A DEGROOT et al. CURRENT OPINION IN PHARMACOLOGY
- Heterogeneity of Monoclonal Antibodies
- (2007) Hongcheng Liu et al. JOURNAL OF PHARMACEUTICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More